Abstracts tagged "Cardiovascular"

Abstract Number: 1976 • ACR Convergence 2022
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Amar Suwal¹, Biraj Shrestha², Ibiyemi Oke² and Anthony Donato², ¹Reading Hospital, Tower Health, Reading, PA, ²reading hospital- tower health, Reading, PA
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
Abstract Number: 0415 • ACR Convergence 2022
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
Jean Liew¹, Timothy Treu², yojin Park², Jacqueline Ferguson³, Morgan Rosser², yuk-Lam Ho², Susan Heckbert⁴, Lianne Gensler⁵, Katherine Liao⁶ and Maureen Dubreuil⁷, ¹Boston University School of Medicine, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Stanford, Palo Alto, CA, ⁴University of Washington, Seattle, WA, ⁵Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: The increased cardiovascular (CV) disease burden in ankylosing spondylitis (AS) is established. Whether tumor necrosis factor inhibitor (TNFi) treatment, particularly when started early in…
Abstract Number: 0885 • ACR Convergence 2022
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
brittany weber¹, Dana Weisenfeld¹, Thany Seyok¹, Elena Massarotti¹, Selena Huang¹, Derrick Todd¹, Jonathan Coblyn¹, michael weinblatt¹, Tianrun Cai¹, Kumar Dahal¹, leanne BArrett¹, Daniel Solomon¹, Jorge Plutzky¹, Marcy Bolster², marcelo Dicarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…
Abstract Number: 1058 • ACR Convergence 2022
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Jessica Fairley¹, Dylan Hansen², Laura Ross³, Susanna Proudman⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Jenny Walker⁷, Lauren Host⁸, Kathleen Morrisroe², Diane Apostolopoulos⁹, Nava Ferdowsi², Michelle Wilson⁹, Maryam Tabesh², Wendy Stevens² and Mandana Nikpour¹⁰, ¹The University of Melbourne, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Monash University, Melbourne, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1649 • ACR Convergence 2022
Five-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management
Lai-shan Tam¹, Tsz On Lam² and Man Choi Wan³, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Prince of Wales Hospital, Hong Kong, Hong Kong, ³Ruttonjee Hospital, Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Rheumatoid arthritis (RA) is known to cause increased risk of cardiovascular (CV) disease (CVD) due to the underlying inflammation. The year of 2010 revolutionised…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…
Abstract Number: 0036 • ACR Convergence 2022
Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort
Junjie Peng¹, George Robinson¹, Stacy P Ardoin², Laura Schanberg³, Elizabeth Jury¹ and Coziana Ciurtin⁴, ¹University College London, London, United Kingdom, ²Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: The risk of developing cardiovascular disease (CVD) through atherosclerosis in juvenile-onset systemic lupus erythematosus (JSLE) patients is significantly increased. This study aimed to stratify…
Abstract Number: 0445 • ACR Convergence 2022
Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
Ana Arevalo¹, Palak Shah², Harshvardhan Zala³, Faris Haddadin⁴, Monil Majmundar⁵ and Andrea Ramirez Gomez¹, ¹University of Chicago, Chicago, IL, ²Metropolitan Hospital Center, New York Medical College, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Several studies have reported that patients with ANCA-associated vasculitis (AAV) are at increased risk of cardiovascular complications from accelerated atherosclerosis with an excess cardiovascular…
Abstract Number: 0893 • ACR Convergence 2022
ATP-Binding Cassette G1 Membrane Transporter-mediated Cholesterol Efflux Capacity Influences Coronary Atherosclerosis and Cardiovascular Risk in RA
George A Karpouzas¹, bianca Papotti², Sarah Ormseth³, Marcella Palumbo², elizabeth Hernandez³, Maria Pia Adorni², Francesca Zimetti⁴, Matthew Budoff⁵ and Nicoletta Ronda⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴University of Parma, Parma, ⁵Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: Cholesterol efflux capacity CEC measures the ability of high-density lipoprotein (HDL) to remove cholesterol from arterial wall macrophages upon interaction with membrane transporter proteins…
Abstract Number: 1195 • ACR Convergence 2022
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
Meghan Corriere, Alyson Dickson, Laura Daniel, Puran Nepal, Kathi Hall, Dale Plummer, William Dupont, Katherine Murray, Michael Stein, Wayne Ray and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…
Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Alice Barinotti¹, Massimo Radin¹, Irene Cecchi², Silvia Grazietta Foddai¹, Simone Baldovino¹, Elisa Menegatti¹, Daniela Rossi¹, Vittorio Modena¹, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…
Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose felix Restrepo Suarez¹, Inmaculada Del Rincon¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science center at San Antonio, San Antonio, TX, ²University of Texas Health Sciences Center San Antonio, San antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…
Abstract Number: 2085 • ACR Convergence 2022
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
Abstract Number: 0042 • ACR Convergence 2022
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Amritha Yellamilli¹, Victoria Osinski², Maria Firulyova³, Jennifer Auger⁴, Lee Meier², Jessica Faragher⁵, Aubyn Marath⁶, Konstantin Zaitsev³ and Bryce Binstadt⁵, ¹Stanford University School of Medicine, Palo Alto, ²University of Minnesota School of Medicine, Minneapolis, MN, ³ITMO University, Saint Petersburg, Russia, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵University of Minnesota, Minneapolis, MN, ⁶CardioStart, Portland
Background/Purpose: Valvular carditis is a serious complication of systemic autoimmune diseases. Although endothelial cells are thought to play an important role in autoimmune valvular carditis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].